Get the Stockscreener App
0.37
46.24%
-0.3183
PaxMedica Inc stock is currently priced at $0.37, with a 24-hour trading volume of 782.87K.
It has seen a -46.24% decreased in the last 24 hours and a -30.19% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7027 pivot point. If it approaches the $0.5158 support level, significant changes may occur.
Previous Close:
$0.6883
Open:
$0.3051
24h Volume:
782.87K
Market Cap:
$2.76M
Revenue:
-
Net Income/Loss:
$-18.29M
P/E Ratio:
-0.0109
EPS:
-34
Net Cash Flow:
$-10.77M
1W Performance:
-47.46%
1M Performance:
-30.19%
6M Performance:
-85.66%
1Y Performance:
-73.77%
1D Range:
$0.305
$0.525
52W Range:
$0.1471
$10.26
PaxMedica Inc Stock (PXMD) Company Profile
Name
PaxMedica Inc
Sector
Industry
Phone
914-987-2876
Address
303 South Broadway, Suite 125, Tarrytown
PaxMedica Inc Stock (PXMD) Latest News
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
GlobeNewswire Inc.
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
GlobeNewswire Inc.
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Benzinga
The Differences Between Good Penny Stocks & Bad Penny Stocks
PennyStocks
Nasdaq Down 300 Points; BlackRock Posts Upbeat Earnings
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
PaxMedica Inc Stock (PXMD) Financials Data
PaxMedica Inc (PXMD) Net Income 2024
PXMD net income (TTM) was -$18.29 million for the quarter ending December 31, 2023, a -23.56% decrease year-over-year.
PaxMedica Inc (PXMD) Cash Flow 2024
PXMD recorded a free cash flow (TTM) of -$10.77 million for the quarter ending December 31, 2023, a -77.37% decrease year-over-year.
PaxMedica Inc (PXMD) Earnings per Share 2024
PXMD earnings per share (TTM) was -$15.18 for the quarter ending December 31, 2023, a +37.92% growth year-over-year.
PaxMedica Inc Stock (PXMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisman Howard J. | Chief Executive Officer |
Jan 29 '24 |
Sale |
0.47 |
372 |
175 |
37,675 |
| LaRochelle Karen | Director |
Jan 29 '24 |
Sale |
0.48 |
78 |
37 |
2,829 |
| Coelho John F | Director |
Jan 29 '24 |
Sale |
0.48 |
27 |
13 |
4,615 |
| Rome Zachary | Director |
Nov 27 '23 |
Sale |
1.03 |
359 |
370 |
15,959 |
| Derby Michael | 10% Owner |
Nov 27 '23 |
Sale |
1.03 |
185 |
190 |
25,650 |
| Weisman Howard J. | Chairman and CEO |
Nov 27 '23 |
Sale |
1.03 |
162 |
166 |
38,047 |
| LaRochelle Karen | Director |
Nov 27 '23 |
Sale |
1.03 |
35 |
36 |
2,907 |
| Coelho John F | Director |
Nov 27 '23 |
Sale |
1.02 |
12 |
12 |
4,642 |
| Rome Zachary | Director |
Oct 27 '23 |
Sale |
0.18 |
16,301 |
3,012 |
277,390 |
| Derby Michael | 10% Owner |
Oct 27 '23 |
Sale |
0.19 |
9,175 |
1,740 |
439,171 |
About PaxMedica Inc
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was founded in 2018 and is based in Tarrytown, New York.
0.56%
3.58%
Cap:
|
Volume (24h):